The endothelin 1 and endothelin receptor A gene polymorphisms increase the risk of developing papillary thyroid cancer


AYDıN A. F., Vural P., Doğru-Abbasoğlu S., ÇIL E.

MOLECULAR BIOLOGY REPORTS, sa.1, ss.199-205, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1007/s11033-018-4461-8
  • Dergi Adı: MOLECULAR BIOLOGY REPORTS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.199-205
  • Anahtar Kelimeler: Papillary thyroid cancer, Endothelin axis, Polymorphism, KAPPA-B, CARCINOMA, AXIS, ASSOCIATION, MECHANISMS, EXPRESSION, DISEASE, PROFILE, G5665T, EDN1
  • İstanbul Üniversitesi Adresli: Evet

Özet

The endothelin (EDN) axis (EDN1 and EDN1 receptor A, EDNRA) is involved in cellular growth, differentiation, invasiveness, and tumor progression in several cancers. We wanted to examine the possible impact of single nucleotide polymorphisms (SNPs) of EDN1 and EDNRA genes on papillary thyroid cancer (PTC) development and general characteristics of PTC. Study population consist of 113 PTC patients and 185 controls. EDN1 (G5665T, T-1370G) and EDNRA (CTT70G, G-231A) SNPs were investigated by real-time PCR. The GG genotype of EDNRA+70 SNP was associated with threefold increased PTC risk (p=0.01), and the combined CG+GG genotype was 2.48 fold higher among PTC patients compared to controls. The variant EDNRA-231 allele was overrepresented in PTC patients according to controls (p=0.05). The combined GT+TT genotype of EDN1 5665 SNP was related with late (age after 40years) PTC onset (p=0.04), and was more prominent among male patients with PTC according to females (p=0.03). No significant associations between PTC and -1370 SNP were found. There were no relationships between laboratory parameters and investigated polymorphisms. The EDNRA+70 SNP was associated with PTC development. The EDN1 5665 SNP was linked with increased risk for late PTC onset and was more prominent among male patients with PTC.